Company news: Merck, Millennium, Novo Nordisk and Genentech

Share this article:

Merck can update its Vytorin label with data suggesting a cardiovascular benefit in patients with kidney disease, the drugmaker said, but may not claim a new indication. That was the FDA's decision, despite a unanimous vote by an advisory panel in favor of the pre-dialysis outcome. The vote had followed release of data from the SHARP trial, in which Vytorin (ezetimibe/simvastatin) reduced major vascular events in patients with moderate-to-severe chronic kidney disease (CKD). The FDA permitted no such label update for Vytorin's LDL-lowering cousin, Zetia (ezetimibe).

Biotechs made a showing in Fortune Magazine's list of 100 Best Companies to Work For, starting with Millennium: The Takeda Oncology Company, which placed at 35 and was followed closely by Novo Nordisk at 43. Genentech was No. 68.

Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.